 Michael Yaron
Concepts (655)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 17 | 2001 | 54 | 1.740 |
Why?
| | Arthritis, Rheumatoid | 49 | 2006 | 1167 | 1.580 |
Why?
| | Altitude Sickness | 10 | 2015 | 153 | 1.220 |
Why?
| | Synovial Membrane | 13 | 2003 | 117 | 0.920 |
Why?
| | Methotrexate | 15 | 1997 | 260 | 0.860 |
Why?
| | Osteoarthritis | 13 | 2003 | 185 | 0.850 |
Why?
| | Hyaluronic Acid | 19 | 2001 | 225 | 0.840 |
Why?
| | Interleukin-1 | 13 | 2004 | 965 | 0.830 |
Why?
| | Saliva | 7 | 2001 | 242 | 0.800 |
Why?
| | Balneology | 4 | 2000 | 4 | 0.490 |
Why?
| | Antibodies, Antinuclear | 7 | 2001 | 71 | 0.480 |
Why?
| | Interleukin-6 | 7 | 2006 | 778 | 0.460 |
Why?
| | Arthritis, Psoriatic | 6 | 2000 | 21 | 0.430 |
Why?
| | Calcium, Dietary | 1 | 2014 | 57 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 123 | 0.420 |
Why?
| | Surveys and Questionnaires | 7 | 2010 | 5778 | 0.420 |
Why?
| | Middle Aged | 88 | 2015 | 33479 | 0.410 |
Why?
| | Communication Barriers | 2 | 2007 | 104 | 0.410 |
Why?
| | Antirheumatic Agents | 8 | 2006 | 293 | 0.400 |
Why?
| | Prostaglandins E | 9 | 1993 | 47 | 0.390 |
Why?
| | Fibromyalgia | 4 | 2009 | 52 | 0.390 |
Why?
| | Female | 118 | 2015 | 73304 | 0.390 |
Why?
| | Nitric Oxide | 4 | 2003 | 915 | 0.390 |
Why?
| | Arteries | 1 | 2014 | 269 | 0.380 |
Why?
| | Rheumatic Diseases | 4 | 2010 | 81 | 0.370 |
Why?
| | Altitude | 5 | 2004 | 488 | 0.370 |
Why?
| | Humans | 169 | 2015 | 137585 | 0.360 |
Why?
| | Low Back Pain | 3 | 1998 | 108 | 0.350 |
Why?
| | Travel | 3 | 2008 | 130 | 0.340 |
Why?
| | Male | 94 | 2015 | 67762 | 0.340 |
Why?
| | Adult | 77 | 2015 | 37929 | 0.330 |
Why?
| | Aged | 57 | 2015 | 23961 | 0.330 |
Why?
| | Medical Order Entry Systems | 1 | 2010 | 43 | 0.320 |
Why?
| | Dietary Supplements | 1 | 2014 | 561 | 0.320 |
Why?
| | Gold | 6 | 1997 | 118 | 0.300 |
Why?
| | Israel | 11 | 2010 | 56 | 0.300 |
Why?
| | Physical Examination | 3 | 2015 | 241 | 0.290 |
Why?
| | Fibroblasts | 15 | 1993 | 996 | 0.290 |
Why?
| | Aurothioglucose | 3 | 1997 | 7 | 0.290 |
Why?
| | Drug Eruptions | 3 | 1997 | 27 | 0.280 |
Why?
| | Child Welfare | 2 | 2008 | 216 | 0.280 |
Why?
| | Spondylitis, Ankylosing | 4 | 2007 | 46 | 0.270 |
Why?
| | Matrix Metalloproteinase 3 | 2 | 2006 | 28 | 0.270 |
Why?
| | Sleep Wake Disorders | 2 | 2004 | 286 | 0.270 |
Why?
| | Synovial Fluid | 6 | 1989 | 68 | 0.270 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2828 | 0.260 |
Why?
| | Knee Joint | 5 | 2003 | 409 | 0.260 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 6 | 2003 | 350 | 0.260 |
Why?
| | Professional-Family Relations | 1 | 2008 | 143 | 0.260 |
Why?
| | Child Behavior | 2 | 2007 | 248 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2004 | 1242 | 0.250 |
Why?
| | Penicillamine | 5 | 1991 | 23 | 0.250 |
Why?
| | Wilderness | 2 | 2015 | 16 | 0.240 |
Why?
| | Lupus Erythematosus, Systemic | 9 | 2003 | 242 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 3 | 2000 | 66 | 0.230 |
Why?
| | Sensitivity and Specificity | 7 | 2010 | 1946 | 0.220 |
Why?
| | Health Education | 1 | 2008 | 341 | 0.220 |
Why?
| | Length of Stay | 1 | 2010 | 1215 | 0.220 |
Why?
| | Heat Stroke | 1 | 2004 | 14 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 8 | 1998 | 2691 | 0.210 |
Why?
| | Hydroxybutyrates | 1 | 2003 | 14 | 0.210 |
Why?
| | Emergency Service, Hospital | 3 | 2010 | 2069 | 0.200 |
Why?
| | Population Surveillance | 1 | 2007 | 482 | 0.200 |
Why?
| | Phytotherapy | 1 | 2003 | 83 | 0.200 |
Why?
| | Osteoarthritis, Knee | 2 | 2003 | 254 | 0.200 |
Why?
| | Anthraquinones | 2 | 2000 | 11 | 0.200 |
Why?
| | Glycosaminoglycans | 4 | 1999 | 83 | 0.200 |
Why?
| | Cervical Vertebrae | 2 | 1995 | 137 | 0.200 |
Why?
| | Prednisone | 8 | 2003 | 240 | 0.190 |
Why?
| | Aniline Compounds | 1 | 2003 | 102 | 0.190 |
Why?
| | Osteonecrosis | 2 | 1996 | 24 | 0.190 |
Why?
| | Wounds and Injuries | 5 | 2015 | 758 | 0.190 |
Why?
| | Dinoprostone | 3 | 1999 | 191 | 0.190 |
Why?
| | Respiration | 1 | 2003 | 199 | 0.190 |
Why?
| | Mud Therapy | 3 | 2000 | 3 | 0.190 |
Why?
| | Receptors, Interleukin-1 | 2 | 2001 | 216 | 0.190 |
Why?
| | Hydroxychloroquine | 2 | 1999 | 58 | 0.180 |
Why?
| | Plant Extracts | 1 | 2003 | 202 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2014 | 2057 | 0.180 |
Why?
| | Minocycline | 5 | 1999 | 27 | 0.180 |
Why?
| | Pulmonary Edema | 2 | 2001 | 108 | 0.180 |
Why?
| | Guanidines | 1 | 2001 | 39 | 0.180 |
Why?
| | Retinal Hemorrhage | 1 | 2001 | 19 | 0.180 |
Why?
| | Prospective Studies | 15 | 2004 | 7604 | 0.170 |
Why?
| | Back Pain | 3 | 2000 | 51 | 0.170 |
Why?
| | Hand | 5 | 2001 | 156 | 0.170 |
Why?
| | Nitric Oxide Synthase | 1 | 2001 | 240 | 0.170 |
Why?
| | Arthritis, Juvenile | 2 | 1992 | 56 | 0.160 |
Why?
| | Calcinosis | 3 | 1998 | 235 | 0.160 |
Why?
| | Amitriptyline | 1 | 1999 | 21 | 0.160 |
Why?
| | Emergency Treatment | 2 | 2004 | 118 | 0.160 |
Why?
| | Resuscitation | 2 | 1994 | 251 | 0.160 |
Why?
| | Fluoxetine | 1 | 1999 | 54 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 3 | 1999 | 565 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1329 | 0.150 |
Why?
| | Amyloidosis | 4 | 2002 | 42 | 0.150 |
Why?
| | Tears | 1 | 1998 | 28 | 0.150 |
Why?
| | Immunosuppressive Agents | 2 | 2003 | 890 | 0.150 |
Why?
| | Aged, 80 and over | 13 | 2010 | 7635 | 0.150 |
Why?
| | Pain Measurement | 6 | 2004 | 521 | 0.150 |
Why?
| | Down-Regulation | 1 | 2001 | 657 | 0.150 |
Why?
| | Antiphospholipid Syndrome | 2 | 1998 | 34 | 0.150 |
Why?
| | Eye Proteins | 1 | 1998 | 92 | 0.150 |
Why?
| | Analgesia, Epidural | 1 | 1998 | 33 | 0.140 |
Why?
| | Leukocytes | 7 | 2002 | 311 | 0.140 |
Why?
| | Biomarkers | 12 | 2000 | 4149 | 0.140 |
Why?
| | Disasters | 1 | 1999 | 98 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 840 | 0.140 |
Why?
| | Cross-Over Studies | 2 | 2014 | 564 | 0.140 |
Why?
| | Osteoporosis | 2 | 1999 | 243 | 0.140 |
Why?
| | Acute Disease | 6 | 2007 | 1007 | 0.130 |
Why?
| | RNA, Small Cytoplasmic | 1 | 1997 | 7 | 0.130 |
Why?
| | Ultraviolet Rays | 1 | 2000 | 396 | 0.130 |
Why?
| | Bronchial Spasm | 1 | 1996 | 6 | 0.130 |
Why?
| | Cells, Cultured | 11 | 2003 | 4193 | 0.130 |
Why?
| | Capnography | 1 | 1996 | 16 | 0.130 |
Why?
| | Antibodies, Antiphospholipid | 1 | 1996 | 25 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 4 | 2003 | 496 | 0.130 |
Why?
| | Hypoxia | 1 | 2004 | 1112 | 0.130 |
Why?
| | Sulfasalazine | 2 | 1997 | 23 | 0.130 |
Why?
| | Mortality | 1 | 1999 | 362 | 0.130 |
Why?
| | Rheumatoid Nodule | 3 | 2001 | 6 | 0.120 |
Why?
| | Thermometers | 1 | 1995 | 8 | 0.120 |
Why?
| | Brown-Sequard Syndrome | 1 | 1995 | 5 | 0.120 |
Why?
| | Thermography | 1 | 1995 | 11 | 0.120 |
Why?
| | Eicosanoids | 1 | 1996 | 62 | 0.120 |
Why?
| | C-Reactive Protein | 5 | 1999 | 410 | 0.120 |
Why?
| | Tympanic Membrane | 1 | 1995 | 21 | 0.120 |
Why?
| | Medical History Taking | 1 | 2015 | 117 | 0.120 |
Why?
| | Cyanoacrylates | 1 | 1995 | 4 | 0.120 |
Why?
| | Mountaineering | 3 | 2008 | 40 | 0.120 |
Why?
| | Joint Deformities, Acquired | 2 | 2000 | 5 | 0.120 |
Why?
| | Foot Ulcer | 1 | 1995 | 3 | 0.120 |
Why?
| | Hand Injuries | 1 | 1995 | 31 | 0.120 |
Why?
| | Tissue Adhesives | 1 | 1995 | 19 | 0.120 |
Why?
| | Cartilage, Articular | 4 | 2001 | 311 | 0.120 |
Why?
| | HLA Antigens | 5 | 1991 | 240 | 0.120 |
Why?
| | HLA-DR Antigens | 2 | 1994 | 228 | 0.120 |
Why?
| | Autoimmune Diseases | 4 | 2000 | 460 | 0.120 |
Why?
| | Jews | 5 | 2009 | 23 | 0.120 |
Why?
| | Hospital Design and Construction | 1 | 1994 | 5 | 0.110 |
Why?
| | Fever | 2 | 1996 | 306 | 0.110 |
Why?
| | Creatinine | 3 | 2014 | 499 | 0.110 |
Why?
| | Colitis, Ulcerative | 1 | 1996 | 136 | 0.110 |
Why?
| | Lacerations | 1 | 1995 | 35 | 0.110 |
Why?
| | Hypersensitivity | 1 | 1998 | 257 | 0.110 |
Why?
| | Administration, Oral | 3 | 2014 | 816 | 0.110 |
Why?
| | Wounds, Penetrating | 1 | 1995 | 65 | 0.110 |
Why?
| | Microbial Collagenase | 3 | 1990 | 12 | 0.110 |
Why?
| | Recommended Dietary Allowances | 1 | 2014 | 18 | 0.110 |
Why?
| | Joints | 4 | 2004 | 105 | 0.110 |
Why?
| | Metacarpophalangeal Joint | 1 | 1993 | 15 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2003 | 852 | 0.110 |
Why?
| | Androgen-Insensitivity Syndrome | 1 | 2013 | 4 | 0.110 |
Why?
| | Environment | 1 | 2015 | 358 | 0.110 |
Why?
| | Phosphorus | 1 | 2014 | 97 | 0.100 |
Why?
| | Parathyroid Hormone | 1 | 2014 | 108 | 0.100 |
Why?
| | Healthy Volunteers | 1 | 2014 | 199 | 0.100 |
Why?
| | Reference Values | 4 | 2007 | 816 | 0.100 |
Why?
| | Time Factors | 14 | 2003 | 6828 | 0.100 |
Why?
| | Calcitriol | 1 | 1993 | 58 | 0.100 |
Why?
| | Random Allocation | 1 | 2014 | 353 | 0.100 |
Why?
| | Growth Inhibitors | 1 | 1993 | 43 | 0.100 |
Why?
| | Blood Sedimentation | 6 | 2000 | 39 | 0.100 |
Why?
| | Octreotide | 2 | 2004 | 26 | 0.100 |
Why?
| | Hydrocortisone | 6 | 2001 | 322 | 0.100 |
Why?
| | Colorado | 4 | 2010 | 4565 | 0.100 |
Why?
| | Radiography | 7 | 2001 | 822 | 0.100 |
Why?
| | Child, Preschool | 8 | 2007 | 11074 | 0.100 |
Why?
| | Synovitis | 4 | 1993 | 27 | 0.100 |
Why?
| | Point Mutation | 1 | 2013 | 235 | 0.100 |
Why?
| | Acute-Phase Reaction | 2 | 1989 | 41 | 0.100 |
Why?
| | Wound Healing | 1 | 1995 | 331 | 0.100 |
Why?
| | Carpal Bones | 1 | 1992 | 14 | 0.090 |
Why?
| | Hyperemia | 1 | 1992 | 49 | 0.090 |
Why?
| | Receptors, Androgen | 1 | 2013 | 150 | 0.090 |
Why?
| | Ulna | 1 | 1992 | 27 | 0.090 |
Why?
| | Eye Diseases | 2 | 1992 | 87 | 0.090 |
Why?
| | Leucovorin | 2 | 1990 | 81 | 0.090 |
Why?
| | Prevalence | 3 | 2010 | 2734 | 0.090 |
Why?
| | Erythema Nodosum | 1 | 1991 | 8 | 0.090 |
Why?
| | Rubella virus | 2 | 1981 | 7 | 0.090 |
Why?
| | Spinal Injuries | 1 | 1992 | 53 | 0.090 |
Why?
| | Measles virus | 2 | 1981 | 16 | 0.090 |
Why?
| | Vitamin D | 2 | 2014 | 397 | 0.090 |
Why?
| | Airway Obstruction | 2 | 1996 | 162 | 0.090 |
Why?
| | Vasculitis | 3 | 2001 | 66 | 0.090 |
Why?
| | Red-Cell Aplasia, Pure | 1 | 1991 | 1 | 0.090 |
Why?
| | Interleukin-10 | 2 | 2006 | 302 | 0.090 |
Why?
| | Myocardial Infarction | 2 | 2014 | 1046 | 0.090 |
Why?
| | Treatment Outcome | 12 | 2004 | 10811 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2007 | 3284 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1992 | 137 | 0.080 |
Why?
| | Arthritis | 4 | 2000 | 95 | 0.080 |
Why?
| | Child | 10 | 2015 | 21935 | 0.080 |
Why?
| | Digital Rectal Examination | 1 | 2010 | 10 | 0.080 |
Why?
| | Interferon-gamma | 2 | 1990 | 789 | 0.080 |
Why?
| | Occult Blood | 1 | 2010 | 34 | 0.080 |
Why?
| | Heart Rate | 1 | 2014 | 822 | 0.080 |
Why?
| | Aspirin | 3 | 2003 | 387 | 0.080 |
Why?
| | Urinary Tract Infections | 1 | 1992 | 188 | 0.080 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2009 | 8 | 0.080 |
Why?
| | Jaundice | 1 | 1989 | 14 | 0.080 |
Why?
| | Diclofenac | 1 | 1989 | 15 | 0.080 |
Why?
| | Poly I-C | 3 | 1980 | 63 | 0.080 |
Why?
| | Spinal Diseases | 1 | 1990 | 48 | 0.080 |
Why?
| | Infant | 7 | 2004 | 9465 | 0.080 |
Why?
| | Ligaments, Articular | 1 | 1990 | 51 | 0.080 |
Why?
| | Intervertebral Disc Displacement | 1 | 1990 | 40 | 0.080 |
Why?
| | Recombinant Proteins | 5 | 1997 | 1353 | 0.080 |
Why?
| | Testosterone | 1 | 2013 | 409 | 0.080 |
Why?
| | Sarcoidosis | 2 | 2002 | 159 | 0.080 |
Why?
| | Temporomandibular Joint Disorders | 1 | 1989 | 9 | 0.080 |
Why?
| | Temporomandibular Joint | 1 | 1989 | 8 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2009 | 57 | 0.080 |
Why?
| | Anti-Bacterial Agents | 5 | 2003 | 1809 | 0.080 |
Why?
| | Anemia, Aplastic | 1 | 1989 | 38 | 0.080 |
Why?
| | Cryoglobulinemia | 1 | 1988 | 5 | 0.080 |
Why?
| | Keratosis | 1 | 1988 | 16 | 0.080 |
Why?
| | Biological Factors | 1 | 1989 | 39 | 0.080 |
Why?
| | Familial Mediterranean Fever | 1 | 1988 | 8 | 0.080 |
Why?
| | Ichthyosis | 1 | 1988 | 13 | 0.080 |
Why?
| | Age Factors | 6 | 2015 | 3295 | 0.080 |
Why?
| | Auranofin | 1 | 1988 | 9 | 0.070 |
Why?
| | Scleroderma, Systemic | 2 | 2000 | 122 | 0.070 |
Why?
| | Lipopolysaccharides | 2 | 2003 | 886 | 0.070 |
Why?
| | alpha 1-Antitrypsin | 1 | 2009 | 108 | 0.070 |
Why?
| | Stomatitis, Aphthous | 1 | 1988 | 10 | 0.070 |
Why?
| | Chyle | 1 | 1988 | 4 | 0.070 |
Why?
| | Immunoglobulins | 1 | 1988 | 171 | 0.070 |
Why?
| | Interferons | 3 | 1980 | 202 | 0.070 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1988 | 87 | 0.070 |
Why?
| | Culture Techniques | 4 | 1999 | 81 | 0.070 |
Why?
| | Diagnosis, Differential | 5 | 2003 | 1483 | 0.070 |
Why?
| | Seasons | 1 | 2010 | 547 | 0.070 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1988 | 128 | 0.070 |
Why?
| | Ligaments | 1 | 1988 | 60 | 0.070 |
Why?
| | Polychondritis, Relapsing | 1 | 1987 | 2 | 0.070 |
Why?
| | Language | 1 | 2010 | 292 | 0.070 |
Why?
| | HLA-B27 Antigen | 1 | 2007 | 16 | 0.070 |
Why?
| | Adolescent | 13 | 2015 | 21513 | 0.070 |
Why?
| | Joint Diseases | 1 | 1988 | 60 | 0.070 |
Why?
| | Edema | 1 | 1988 | 130 | 0.070 |
Why?
| | Skin | 5 | 2003 | 752 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2010 | 786 | 0.070 |
Why?
| | Academic Medical Centers | 1 | 2010 | 512 | 0.070 |
Why?
| | Cysts | 1 | 1988 | 113 | 0.070 |
Why?
| | Remission Induction | 3 | 1993 | 288 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2003 | 1993 | 0.070 |
Why?
| | Demography | 2 | 1999 | 291 | 0.060 |
Why?
| | Blood Proteins | 1 | 1988 | 252 | 0.060 |
Why?
| | Chronic Disease | 4 | 2015 | 1793 | 0.060 |
Why?
| | Indomethacin | 4 | 1989 | 81 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1999 | 180 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2004 | 1430 | 0.060 |
Why?
| | Kidney | 4 | 2003 | 1468 | 0.060 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2006 | 22 | 0.060 |
Why?
| | Syndrome | 4 | 1993 | 358 | 0.060 |
Why?
| | Primary Prevention | 1 | 2008 | 196 | 0.060 |
Why?
| | Spine | 1 | 1988 | 173 | 0.060 |
Why?
| | Monitoring, Physiologic | 2 | 2004 | 275 | 0.060 |
Why?
| | Liver | 2 | 1992 | 1943 | 0.060 |
Why?
| | Isoxazoles | 1 | 2006 | 54 | 0.060 |
Why?
| | Sialoglycoproteins | 2 | 2000 | 159 | 0.060 |
Why?
| | Shoulder Joint | 1 | 1988 | 173 | 0.060 |
Why?
| | Proteinuria | 2 | 2002 | 97 | 0.060 |
Why?
| | Pedigree | 4 | 2000 | 514 | 0.060 |
Why?
| | Oxygen | 3 | 2003 | 931 | 0.060 |
Why?
| | Incidence | 3 | 2002 | 2804 | 0.060 |
Why?
| | Rheumatoid Factor | 2 | 2001 | 175 | 0.060 |
Why?
| | Stimulation, Chemical | 4 | 1989 | 59 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2000 | 1236 | 0.060 |
Why?
| | Sports | 2 | 2015 | 231 | 0.060 |
Why?
| | Ankle Joint | 2 | 2002 | 114 | 0.050 |
Why?
| | Cell Division | 4 | 1993 | 794 | 0.050 |
Why?
| | Biopsy, Needle | 2 | 1999 | 189 | 0.050 |
Why?
| | Uric Acid | 3 | 2003 | 163 | 0.050 |
Why?
| | Oximetry | 2 | 2003 | 96 | 0.050 |
Why?
| | Autoantibodies | 4 | 1999 | 1496 | 0.050 |
Why?
| | Retrospective Studies | 9 | 2010 | 15657 | 0.050 |
Why?
| | Crohn Disease | 2 | 2004 | 243 | 0.050 |
Why?
| | Crotonates | 1 | 2003 | 5 | 0.050 |
Why?
| | Toluidines | 1 | 2003 | 7 | 0.050 |
Why?
| | Tenosynovitis | 1 | 2003 | 11 | 0.050 |
Why?
| | Patient Discharge | 1 | 2010 | 897 | 0.050 |
Why?
| | Inflammation | 3 | 1989 | 2837 | 0.050 |
Why?
| | Mycobacterium kansasii | 1 | 2003 | 15 | 0.050 |
Why?
| | Acne Vulgaris | 3 | 1998 | 29 | 0.050 |
Why?
| | Pemphigus | 1 | 1983 | 8 | 0.050 |
Why?
| | Tuberculosis, Miliary | 1 | 2003 | 5 | 0.050 |
Why?
| | Tuberculosis, Cutaneous | 1 | 2003 | 3 | 0.050 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2003 | 27 | 0.050 |
Why?
| | Hypnosis | 1 | 1983 | 11 | 0.050 |
Why?
| | Fasciitis | 1 | 1982 | 12 | 0.050 |
Why?
| | Lip | 2 | 2001 | 24 | 0.050 |
Why?
| | Wakefulness | 1 | 2004 | 125 | 0.050 |
Why?
| | Cell Survival | 2 | 2003 | 1120 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 1999 | 5131 | 0.050 |
Why?
| | Technetium Tc 99m Exametazime | 1 | 2002 | 2 | 0.050 |
Why?
| | Lipoproteins | 1 | 1983 | 168 | 0.050 |
Why?
| | Spondylarthropathies | 1 | 2002 | 6 | 0.050 |
Why?
| | Tidal Volume | 1 | 2003 | 86 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 184 | 0.050 |
Why?
| | Immunoglobulin G | 3 | 2001 | 893 | 0.050 |
Why?
| | Glucocorticoids | 3 | 2002 | 594 | 0.050 |
Why?
| | History, 20th Century | 1 | 2004 | 325 | 0.050 |
Why?
| | Tuberculosis, Osteoarticular | 1 | 2002 | 4 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 2003 | 600 | 0.050 |
Why?
| | Arthritis, Experimental | 1 | 2004 | 147 | 0.050 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2000 | 42 | 0.050 |
Why?
| | Radionuclide Imaging | 3 | 2002 | 118 | 0.050 |
Why?
| | Nitriles | 1 | 2003 | 172 | 0.050 |
Why?
| | Hepatitis B Vaccines | 1 | 2002 | 45 | 0.050 |
Why?
| | Biopsy | 2 | 1999 | 1129 | 0.050 |
Why?
| | Newcastle disease virus | 1 | 1981 | 17 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2009 | 2426 | 0.050 |
Why?
| | Adenoviruses, Human | 1 | 1981 | 27 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2009 | 530 | 0.050 |
Why?
| | Complement C3b | 1 | 2001 | 34 | 0.050 |
Why?
| | Athletes | 2 | 2015 | 423 | 0.050 |
Why?
| | Family Health | 2 | 1994 | 196 | 0.050 |
Why?
| | Hepatitis B | 1 | 2002 | 70 | 0.050 |
Why?
| | Movement | 1 | 2004 | 278 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2003 | 202 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2002 | 178 | 0.050 |
Why?
| | fas Receptor | 1 | 2001 | 95 | 0.050 |
Why?
| | Prednisolone | 2 | 1992 | 83 | 0.040 |
Why?
| | Emergencies | 2 | 1996 | 164 | 0.040 |
Why?
| | Environmental Medicine | 1 | 2001 | 2 | 0.040 |
Why?
| | Nitroprusside | 1 | 2001 | 69 | 0.040 |
Why?
| | Gastric Antral Vascular Ectasia | 1 | 2000 | 2 | 0.040 |
Why?
| | Young Adult | 2 | 2015 | 13209 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2003 | 243 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2003 | 267 | 0.040 |
Why?
| | Xanthine | 1 | 2000 | 7 | 0.040 |
Why?
| | Hemoglobins | 1 | 2003 | 353 | 0.040 |
Why?
| | Salivary Glands | 2 | 1997 | 33 | 0.040 |
Why?
| | Pneumococcal Vaccines | 1 | 2001 | 142 | 0.040 |
Why?
| | Xanthine Dehydrogenase | 1 | 2000 | 25 | 0.040 |
Why?
| | Monocytes | 2 | 2001 | 563 | 0.040 |
Why?
| | Eosinophilia | 1 | 1982 | 218 | 0.040 |
Why?
| | Skiing | 1 | 2001 | 47 | 0.040 |
Why?
| | Leg | 2 | 1996 | 236 | 0.040 |
Why?
| | Sulfur Radioisotopes | 1 | 1999 | 15 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2000 | 164 | 0.040 |
Why?
| | Drug Therapy, Combination | 4 | 2003 | 1066 | 0.040 |
Why?
| | Haplotypes | 2 | 1992 | 494 | 0.040 |
Why?
| | Neck Pain | 1 | 2000 | 26 | 0.040 |
Why?
| | Fractures, Stress | 1 | 2000 | 34 | 0.040 |
Why?
| | United States | 3 | 2008 | 14841 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2003 | 1316 | 0.040 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 1999 | 30 | 0.040 |
Why?
| | HLA-DR4 Antigen | 2 | 1992 | 78 | 0.040 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 1999 | 45 | 0.040 |
Why?
| | DNA, Viral | 1 | 1981 | 364 | 0.040 |
Why?
| | Anxiety Disorders | 1 | 1983 | 377 | 0.040 |
Why?
| | Endotoxins | 1 | 1980 | 220 | 0.040 |
Why?
| | Alkaline Phosphatase | 2 | 1992 | 148 | 0.040 |
Why?
| | Xerostomia | 1 | 1999 | 17 | 0.040 |
Why?
| | Age of Onset | 1 | 2001 | 518 | 0.040 |
Why?
| | Lipids | 1 | 1983 | 672 | 0.040 |
Why?
| | Translations | 1 | 1999 | 17 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 1992 | 786 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 123 | 0.040 |
Why?
| | Hemiplegia | 1 | 1998 | 21 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2000 | 170 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2000 | 132 | 0.040 |
Why?
| | Mycobacterium tuberculosis | 1 | 2002 | 314 | 0.040 |
Why?
| | Lumbosacral Region | 2 | 1990 | 58 | 0.040 |
Why?
| | Drug Synergism | 2 | 1990 | 382 | 0.040 |
Why?
| | Recurrence | 2 | 1992 | 1060 | 0.040 |
Why?
| | Pilot Projects | 3 | 2004 | 1710 | 0.040 |
Why?
| | Paresis | 1 | 1998 | 30 | 0.040 |
Why?
| | Infant Behavior | 1 | 1998 | 25 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2000 | 236 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 4 | 2002 | 3566 | 0.040 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2003 | 363 | 0.040 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1997 | 9 | 0.040 |
Why?
| | Health Status | 2 | 2004 | 792 | 0.040 |
Why?
| | Appetite | 1 | 1998 | 69 | 0.040 |
Why?
| | Lactoferrin | 1 | 1997 | 31 | 0.040 |
Why?
| | RNA, Viral | 1 | 1981 | 656 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 1997 | 50 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 665 | 0.030 |
Why?
| | Polymyalgia Rheumatica | 1 | 1997 | 3 | 0.030 |
Why?
| | Electrolytes | 1 | 1997 | 58 | 0.030 |
Why?
| | Cartilage | 1 | 1999 | 188 | 0.030 |
Why?
| | Folic Acid Antagonists | 1 | 1997 | 9 | 0.030 |
Why?
| | Respiratory Hypersensitivity | 1 | 1998 | 69 | 0.030 |
Why?
| | Prognosis | 2 | 1996 | 4030 | 0.030 |
Why?
| | Gene Frequency | 2 | 2009 | 521 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2002 | 351 | 0.030 |
Why?
| | Forced Expiratory Flow Rates | 1 | 1996 | 14 | 0.030 |
Why?
| | Appendicitis | 1 | 1998 | 130 | 0.030 |
Why?
| | Dermatitis, Allergic Contact | 1 | 1998 | 73 | 0.030 |
Why?
| | Psoriasis | 2 | 2000 | 102 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 1997 | 126 | 0.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 123 | 0.030 |
Why?
| | Pain Clinics | 1 | 1996 | 4 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 1998 | 90 | 0.030 |
Why?
| | Blood Platelets | 2 | 1978 | 408 | 0.030 |
Why?
| | Patella | 1 | 1996 | 26 | 0.030 |
Why?
| | Chiropractic | 1 | 1996 | 7 | 0.030 |
Why?
| | Thromboxane B2 | 1 | 1996 | 26 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2031 | 0.030 |
Why?
| | Acupuncture Therapy | 1 | 1996 | 21 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1996 | 173 | 0.030 |
Why?
| | Cohort Studies | 3 | 1998 | 5742 | 0.030 |
Why?
| | Risk Assessment | 2 | 2015 | 3457 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1996 | 134 | 0.030 |
Why?
| | Menopause | 1 | 1999 | 320 | 0.030 |
Why?
| | Mouth Diseases | 1 | 1996 | 45 | 0.030 |
Why?
| | Wilderness Medicine | 1 | 2015 | 11 | 0.030 |
Why?
| | Ribonucleoproteins | 1 | 1997 | 105 | 0.030 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1995 | 28 | 0.030 |
Why?
| | Poliomyelitis | 1 | 1995 | 37 | 0.030 |
Why?
| | Thrombophlebitis | 1 | 1995 | 10 | 0.030 |
Why?
| | Risk Factors | 4 | 2015 | 10388 | 0.030 |
Why?
| | Abdomen | 2 | 2002 | 125 | 0.030 |
Why?
| | Reference Standards | 1 | 1995 | 186 | 0.030 |
Why?
| | Maintenance and Engineering, Hospital | 1 | 1994 | 2 | 0.030 |
Why?
| | Food Hypersensitivity | 1 | 1998 | 183 | 0.030 |
Why?
| | Mutation | 2 | 2009 | 3958 | 0.030 |
Why?
| | Blotting, Western | 1 | 1997 | 1226 | 0.030 |
Why?
| | Pregnancy | 4 | 2015 | 6763 | 0.030 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 3 | 1999 | 36 | 0.030 |
Why?
| | Angiography | 1 | 1995 | 207 | 0.030 |
Why?
| | Rectum | 1 | 1995 | 185 | 0.030 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 1993 | 3 | 0.030 |
Why?
| | Autoantigens | 1 | 1997 | 430 | 0.030 |
Why?
| | Cholesterol | 2 | 1988 | 410 | 0.030 |
Why?
| | Macrophages | 1 | 2001 | 1547 | 0.030 |
Why?
| | Semen Analysis | 1 | 2013 | 14 | 0.030 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2013 | 8 | 0.030 |
Why?
| | Sperm Count | 1 | 2013 | 19 | 0.030 |
Why?
| | Ischemia | 1 | 1996 | 409 | 0.030 |
Why?
| | Hyperostosis, Sternocostoclavicular | 1 | 1993 | 1 | 0.030 |
Why?
| | Infertility, Male | 1 | 2013 | 61 | 0.030 |
Why?
| | Collagenases | 1 | 1993 | 25 | 0.030 |
Why?
| | Infliximab | 2 | 2004 | 111 | 0.030 |
Why?
| | Parents | 1 | 2002 | 1347 | 0.030 |
Why?
| | Linear Models | 1 | 1995 | 849 | 0.020 |
Why?
| | Analgesics | 1 | 1995 | 206 | 0.020 |
Why?
| | Rats | 3 | 2004 | 5647 | 0.020 |
Why?
| | Cervical Atlas | 1 | 1992 | 4 | 0.020 |
Why?
| | Apoptosis | 1 | 2001 | 2553 | 0.020 |
Why?
| | Axis, Cervical Vertebra | 1 | 1992 | 7 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 307 | 0.020 |
Why?
| | Transaminases | 1 | 1992 | 24 | 0.020 |
Why?
| | Blood Urea Nitrogen | 2 | 2003 | 54 | 0.020 |
Why?
| | Radius | 1 | 1992 | 39 | 0.020 |
Why?
| | Atmosphere Exposure Chambers | 1 | 1991 | 7 | 0.020 |
Why?
| | Sleep | 1 | 1998 | 755 | 0.020 |
Why?
| | Serotyping | 1 | 1991 | 32 | 0.020 |
Why?
| | Pain | 2 | 2001 | 756 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1995 | 810 | 0.020 |
Why?
| | Collagen | 2 | 1991 | 452 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1993 | 184 | 0.020 |
Why?
| | Hyperbaric Oxygenation | 1 | 1991 | 39 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 2003 | 160 | 0.020 |
Why?
| | Infant, Newborn | 4 | 2013 | 6079 | 0.020 |
Why?
| | Dactinomycin | 2 | 1987 | 28 | 0.020 |
Why?
| | Drug Antagonism | 1 | 1990 | 10 | 0.020 |
Why?
| | Logistic Models | 1 | 1996 | 2074 | 0.020 |
Why?
| | Crystallization | 2 | 1988 | 143 | 0.020 |
Why?
| | Infant, Premature | 1 | 1995 | 574 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 1995 | 553 | 0.020 |
Why?
| | Antibody Formation | 3 | 2002 | 298 | 0.020 |
Why?
| | Dyspnea | 1 | 1992 | 254 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2004 | 4295 | 0.020 |
Why?
| | Anticoagulants | 1 | 1995 | 664 | 0.020 |
Why?
| | Spinal Stenosis | 1 | 1990 | 30 | 0.020 |
Why?
| | Self Concept | 1 | 1991 | 253 | 0.020 |
Why?
| | Drug Combinations | 1 | 1990 | 343 | 0.020 |
Why?
| | Etidronic Acid | 2 | 1999 | 5 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2486 | 0.020 |
Why?
| | Mandibular Condyle | 1 | 1989 | 6 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1989 | 206 | 0.020 |
Why?
| | Asthma | 3 | 2003 | 2295 | 0.020 |
Why?
| | Congo Red | 1 | 1988 | 9 | 0.020 |
Why?
| | Accidents | 1 | 1989 | 37 | 0.020 |
Why?
| | Raynaud Disease | 1 | 1988 | 5 | 0.020 |
Why?
| | Smoking | 1 | 1996 | 1627 | 0.020 |
Why?
| | HLA-A Antigens | 2 | 1993 | 55 | 0.020 |
Why?
| | HLA-B35 Antigen | 1 | 1988 | 3 | 0.020 |
Why?
| | Azathioprine | 2 | 1992 | 54 | 0.020 |
Why?
| | Periarthritis | 1 | 1988 | 1 | 0.020 |
Why?
| | Staining and Labeling | 1 | 1988 | 150 | 0.020 |
Why?
| | Serum Amyloid P-Component | 1 | 1987 | 3 | 0.020 |
Why?
| | Calcium Phosphates | 1 | 1988 | 27 | 0.020 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 167 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1993 | 527 | 0.020 |
Why?
| | Coronary Disease | 2 | 1995 | 385 | 0.020 |
Why?
| | Cycloheximide | 1 | 1987 | 55 | 0.020 |
Why?
| | Complement C4 | 1 | 1987 | 28 | 0.020 |
Why?
| | Population | 1 | 2007 | 35 | 0.020 |
Why?
| | Vaccination | 1 | 1995 | 1381 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 1070 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 891 | 0.020 |
Why?
| | Accidental Falls | 1 | 1989 | 196 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 1988 | 257 | 0.020 |
Why?
| | Iran | 2 | 2000 | 43 | 0.010 |
Why?
| | Hereditary Sensory and Autonomic Neuropathies | 1 | 1985 | 3 | 0.010 |
Why?
| | Aging | 1 | 2015 | 1864 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1986 | 167 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2000 | 253 | 0.010 |
Why?
| | Pyoderma Gangrenosum | 1 | 2004 | 9 | 0.010 |
Why?
| | Cytokines | 2 | 1990 | 2085 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 2004 | 114 | 0.010 |
Why?
| | Adipose Tissue | 1 | 1988 | 635 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2004 | 129 | 0.010 |
Why?
| | Animals | 6 | 2004 | 36940 | 0.010 |
Why?
| | Bone Marrow Examination | 1 | 1982 | 5 | 0.010 |
Why?
| | Debridement | 1 | 2003 | 81 | 0.010 |
Why?
| | Cell Aggregation | 3 | 1988 | 26 | 0.010 |
Why?
| | Hypergammaglobulinemia | 1 | 1982 | 9 | 0.010 |
Why?
| | Splenomegaly | 1 | 1982 | 15 | 0.010 |
Why?
| | Finger Joint | 1 | 1982 | 8 | 0.010 |
Why?
| | Measles Vaccine | 1 | 1982 | 21 | 0.010 |
Why?
| | Hepatitis B Antibodies | 1 | 2002 | 11 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1431 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2002 | 24 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1991 | 1996 | 0.010 |
Why?
| | Myositis | 1 | 1982 | 52 | 0.010 |
Why?
| | Serologic Tests | 1 | 2002 | 54 | 0.010 |
Why?
| | Measles | 1 | 1982 | 46 | 0.010 |
Why?
| | Phospholipids | 1 | 1983 | 223 | 0.010 |
Why?
| | Elbow Joint | 1 | 1982 | 71 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2003 | 389 | 0.010 |
Why?
| | Opsonin Proteins | 1 | 2001 | 25 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1982 | 69 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1983 | 347 | 0.010 |
Why?
| | Wrist | 1 | 2002 | 54 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2189 | 0.010 |
Why?
| | Chondrocalcinosis | 1 | 2001 | 2 | 0.010 |
Why?
| | Triglycerides | 1 | 1983 | 524 | 0.010 |
Why?
| | Receptors, Complement | 1 | 2001 | 122 | 0.010 |
Why?
| | Clinical Chemistry Tests | 1 | 2001 | 11 | 0.010 |
Why?
| | Occupations | 1 | 2001 | 49 | 0.010 |
Why?
| | Hematologic Tests | 1 | 2001 | 22 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 2000 | 3 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 2001 | 146 | 0.010 |
Why?
| | Thyroid Diseases | 1 | 2001 | 36 | 0.010 |
Why?
| | Therapeutic Equivalency | 1 | 2000 | 32 | 0.010 |
Why?
| | Etanercept | 1 | 2000 | 57 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1982 | 367 | 0.010 |
Why?
| | Salmonella typhi | 1 | 1980 | 13 | 0.010 |
Why?
| | Delayed-Action Preparations | 1 | 2001 | 181 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2000 | 26 | 0.010 |
Why?
| | Brain Edema | 1 | 2001 | 61 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2001 | 431 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 312 | 0.010 |
Why?
| | Reoperation | 1 | 2003 | 573 | 0.010 |
Why?
| | Pneumococcal Infections | 1 | 2001 | 115 | 0.010 |
Why?
| | Shigella flexneri | 1 | 1980 | 15 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 2000 | 2139 | 0.010 |
Why?
| | Placebos | 1 | 2000 | 199 | 0.010 |
Why?
| | Antitubercular Agents | 1 | 2002 | 206 | 0.010 |
Why?
| | Laser Coagulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Furosemide | 1 | 2000 | 37 | 0.010 |
Why?
| | Diuretics | 1 | 2000 | 74 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2000 | 297 | 0.010 |
Why?
| | Serum Sickness | 1 | 1999 | 6 | 0.010 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2000 | 132 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2000 | 168 | 0.010 |
Why?
| | Hepatitis, Autoimmune | 1 | 1999 | 20 | 0.010 |
Why?
| | Folic Acid | 2 | 1990 | 186 | 0.010 |
Why?
| | Freezing | 2 | 1969 | 90 | 0.010 |
Why?
| | Endoscopy, Digestive System | 1 | 2000 | 136 | 0.010 |
Why?
| | Calcitonin | 1 | 1999 | 27 | 0.010 |
Why?
| | Serum Albumin | 1 | 2000 | 150 | 0.010 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1998 | 11 | 0.010 |
Why?
| | Gene Expression | 1 | 2004 | 1502 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1999 | 67 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2000 | 560 | 0.010 |
Why?
| | Arthralgia | 1 | 1998 | 56 | 0.010 |
Why?
| | Appendectomy | 1 | 1998 | 79 | 0.010 |
Why?
| | Kinetics | 1 | 2001 | 1670 | 0.010 |
Why?
| | Estrogen Replacement Therapy | 1 | 1999 | 146 | 0.010 |
Why?
| | Laparotomy | 1 | 1998 | 109 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2000 | 363 | 0.010 |
Why?
| | Functional Laterality | 1 | 1998 | 223 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2671 | 0.010 |
Why?
| | Gold Radioisotopes | 1 | 1977 | 1 | 0.010 |
Why?
| | Lymphocytes | 2 | 1969 | 397 | 0.010 |
Why?
| | Poly I | 1 | 1976 | 1 | 0.010 |
Why?
| | Poly A-U | 1 | 1976 | 4 | 0.010 |
Why?
| | Poly C | 1 | 1976 | 4 | 0.010 |
Why?
| | Yttrium Radioisotopes | 1 | 1977 | 57 | 0.010 |
Why?
| | Sacroiliac Joint | 1 | 1997 | 33 | 0.010 |
Why?
| | Occupational Diseases | 1 | 1998 | 156 | 0.010 |
Why?
| | Skin Diseases, Vascular | 1 | 1996 | 9 | 0.010 |
Why?
| | Base Sequence | 1 | 2000 | 2181 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1978 | 1092 | 0.010 |
Why?
| | Peroxidase | 1 | 1996 | 175 | 0.010 |
Why?
| | Escherichia coli | 1 | 1980 | 815 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 2833 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2003 | 3556 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2001 | 766 | 0.010 |
Why?
| | Infant Welfare | 1 | 1995 | 9 | 0.010 |
Why?
| | Vaccines, Inactivated | 1 | 1995 | 68 | 0.010 |
Why?
| | Sex Factors | 1 | 2001 | 2071 | 0.010 |
Why?
| | Bone Density | 1 | 1999 | 489 | 0.010 |
Why?
| | Glucose | 2 | 1969 | 1020 | 0.010 |
Why?
| | Spirometry | 1 | 1995 | 281 | 0.010 |
Why?
| | Europe | 1 | 1994 | 414 | 0.010 |
Why?
| | Body Mass Index | 1 | 2000 | 2389 | 0.010 |
Why?
| | Necrosis | 1 | 1972 | 246 | 0.010 |
Why?
| | Cell Line | 1 | 1976 | 2847 | 0.010 |
Why?
| | Osteomyelitis | 1 | 1993 | 132 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1972 | 143 | 0.010 |
Why?
| | Endopeptidases | 1 | 1990 | 90 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1991 | 137 | 0.010 |
Why?
| | Spondylitis | 1 | 1969 | 2 | 0.010 |
Why?
| | Dinitrophenols | 1 | 1969 | 8 | 0.010 |
Why?
| | Depression, Chemical | 1 | 1989 | 23 | 0.000 |
Why?
| | Lactates | 1 | 1969 | 85 | 0.000 |
Why?
| | Hydrogen | 1 | 1969 | 70 | 0.000 |
Why?
| | Lymphoma | 1 | 1990 | 208 | 0.000 |
Why?
| | Drug Interactions | 1 | 1990 | 410 | 0.000 |
Why?
| | Interleukin-2 | 1 | 1990 | 455 | 0.000 |
Why?
| | Health Promotion | 1 | 1995 | 741 | 0.000 |
Why?
| | Immunity, Cellular | 1 | 1990 | 268 | 0.000 |
Why?
| | Tumor Cells, Cultured | 1 | 1990 | 955 | 0.000 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2003 | 2531 | 0.000 |
Why?
| | Quality of Life | 1 | 2000 | 2892 | 0.000 |
Why?
| | Multiple Trauma | 1 | 1989 | 100 | 0.000 |
Why?
| | Arthrography | 1 | 1988 | 17 | 0.000 |
Why?
| | Lung Diseases | 1 | 1995 | 767 | 0.000 |
Why?
| | Mice | 3 | 1990 | 17787 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1987 | 157 | 0.000 |
Why?
| | Iodine Radioisotopes | 1 | 1987 | 145 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1987 | 332 | 0.000 |
Why?
| | Autoimmunity | 1 | 1993 | 908 | 0.000 |
Why?
| | Cell Adhesion | 1 | 1988 | 466 | 0.000 |
Why?
| | Hemodynamics | 1 | 1991 | 1113 | 0.000 |
Why?
| | Hypertension | 1 | 1995 | 1295 | 0.000 |
Why?
| | Suicide, Attempted | 1 | 1989 | 378 | 0.000 |
Why?
| | Poland | 1 | 1985 | 35 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 329 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1987 | 250 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1985 | 307 | 0.000 |
Why?
| | Virus Diseases | 1 | 1987 | 212 | 0.000 |
Why?
| | Amyloid | 1 | 1985 | 87 | 0.000 |
Why?
| | Vitreous Body | 1 | 1985 | 110 | 0.000 |
Why?
| | Erythrocytes | 1 | 1969 | 700 | 0.000 |
Why?
| | Preoperative Care | 1 | 1986 | 362 | 0.000 |
Why?
| | HLA-DR1 Antigen | 1 | 1982 | 1 | 0.000 |
Why?
| | Injections, Intra-Articular | 1 | 1982 | 49 | 0.000 |
Why?
| | Tuberculosis | 1 | 1986 | 279 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1982 | 362 | 0.000 |
Why?
| | Neutrophils | 1 | 1985 | 1238 | 0.000 |
Why?
| | Lung Neoplasms | 1 | 1986 | 2526 | 0.000 |
Why?
| | Methods | 1 | 1972 | 65 | 0.000 |
Why?
| | Knee | 1 | 1972 | 68 | 0.000 |
Why?
|
|
Yaron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|